Company Presentation

Onward Therapeutics is a development stage oncology company, focusing on the identification and development of innovative cancer therapies. The company adopts a ‘Buy-to-Build´business model of licensing potential candidates and/or investing in their partners with platform technologies. The two lead programs are a bispecific antibody (OT-A201) and a NK cell-based therapy (NK-001), which are expected to enter into human clinical trials in 2023 and 2024, respectively.